Core Viewpoint - Nearly 20 Hong Kong-listed companies have announced their performance forecasts for the year ending December 31, 2025, with 11 companies expecting profit increases, 2 companies anticipating reduced losses, and 1 company projecting a turnaround to profitability [1] Group 1: Gold Mining Sector - Gold mining companies are showing strong performance, driven by rising gold prices and increased production capacity [2] - Lingbao Gold expects a net profit of 1.503 billion to 1.573 billion RMB for 2025, representing a year-on-year growth of 115% to 125%, attributed to optimized production and increased gold output [2] - Zijin Mining International anticipates a net profit of 1.5 billion to 1.6 billion USD for 2025, with a growth of 212% to 233%, driven by higher gold sales prices and profitable acquisitions [2] - Zijin Mining's parent company, Zijin Mining Group, forecasts a net profit of 51 billion to 52 billion RMB for 2025, reflecting a growth of 59% to 62% [3] - Chifeng Jilong Gold expects a net profit of 3 billion to 3.2 billion RMB for 2025, with a growth of 70% to 81%, due to increased gold production and higher sales prices [3] - Multiple gold mining companies are benefiting from a rising gold price cycle, achieving both volume and price increases [4] Group 2: Biopharmaceutical and Consumer Sectors - The biopharmaceutical and consumer sectors also have companies projecting strong performance for 2025 [5] - WuXi AppTec expects an adjusted net profit of 14.957 billion RMB for 2025, a year-on-year increase of approximately 41.33%, driven by its integrated CRDMO business model [5] - Biotech company Baidu Bio expects a non-GAAP net profit of approximately 80.273 million RMB for 2025, reflecting a growth of about 249.50%, supported by strong R&D capabilities and market expansion [5] - Yadea Holdings anticipates a net profit of no less than 2.9 billion RMB for 2025, doubling from 1.27 billion RMB in 2024, due to increased sales of electric two-wheelers [5] Group 3: Operational Efficiency and Growth - Many Hong Kong-listed companies are achieving performance growth through improved operational efficiency and increased product sales [7] - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion RMB for 2025, with a growth of 149.61% to 196.88%, driven by increased revenue and improved production efficiency [7] - Kinglong Permanent Magnet anticipates a net profit of 660 million to 760 million RMB for 2025, reflecting a growth of 127% to 161%, due to record high production and sales [7] - Sanhua Intelligent Controls expects a net profit of 3.874 billion to 4.649 billion RMB for 2025, with a growth of 25% to 50%, supported by its leading position in the automotive thermal management sector [8]

Core Insights - Approximately 130 A-share companies have disclosed their performance forecasts for 2025, with around 70 companies expecting positive results, including profit increases and turnaround from losses [2][4]. Company Performance Highlights - **Zhongke Lanyun**: Expected net profit of 1.4 billion to 1.43 billion yuan, a year-on-year increase of 366.51% to 376.51%, driven by strategic investments in high-growth areas like GPU and advanced packaging [4][5]. - **Chuanhua Zhili**: Forecasted net profit of 540 million to 700 million yuan, with a growth rate of 256.07% to 361.57%, supported by optimized marketing strategies and asset structure in logistics and chemical businesses [5]. - **Bai'ao Saitou**: Anticipated net profit of 135 million yuan, reflecting a 303.57% increase, attributed to favorable market conditions [4]. - **Kangchen Pharmaceutical**: Expected net profit of 145 million to 175 million yuan, with a growth of 243% to 315%, due to the absence of goodwill impairment losses in the reporting period [5]. - **Guangku Technology**: Projected net profit of 169 million to 182 million yuan, a growth of 152% to 172%, driven by product innovation and cost control [7]. - **Lixun Precision**: Forecasted net profit of 16.518 billion to 17.186 billion yuan, with a growth of 23.59% to 28.59%, supported by innovations in manufacturing and AI integration [6]. - **Daotong Technology**: Expected net profit of 900 million to 930 million yuan, with a growth of 40.42% to 45.10%, driven by AI-driven services [6]. - **Aibisen**: Anticipated net profit of 240 million to 290 million yuan, reflecting a growth of 105.32% to 148.09%, due to increased R&D investment [7]. - **Chaohongji**: Expected net profit of 436 million to 533 million yuan, with a growth of 125% to 175%, supported by a focus on brand optimization and digital transformation [9]. - **WuXi AppTec**: Forecasted net profit of 19.151 billion yuan, with a growth of approximately 102.65%, including gains from divesting joint ventures [9]. - **Hui Sheng Biological**: Expected net profit of 23.5 million to 27.1 million yuan, indicating a turnaround, driven by market expansion and improved production efficiency [9]. Industry Performance Insights - The electronics, semiconductor, pharmaceutical, and machinery sectors are showing strong performance among listed companies [3].

Group 1 - The ChiNext Mid-Cap 200 Index rose by 5.0%, the ChiNext Growth Index increased by 2.3%, and the overall ChiNext Index went up by 1.8% as of the market close [1] - The total trading volume of the E Fund ChiNext ETF (159915) reached 7.3 billion yuan, significantly higher than the previous trading day [1] - China Galaxy Securities highlighted that there are substantial opportunities for rotation in the technology innovation and growth sectors during the spring market rally, with a focus on key areas such as artificial intelligence, embodied intelligence, new energy, controllable nuclear fusion, quantum technology, and aerospace [1] Group 2 - The ChiNext Growth ETF tracks the ChiNext Growth Index, which consists of 50 stocks characterized by strong growth, good earnings expectations, and high liquidity, with the information technology sector accounting for over 40% of the index [3] - The combined share of the telecommunications, power equipment, electronics, computers, and pharmaceutical biotechnology sectors in the ChiNext Growth Index is nearly 85% [3] - The ChiNext Index was launched on June 1, 2010, and the ChiNext Mid-Cap 200 Index was introduced on November 15, 2023 [3]

Group 1 - Public fund institutions accelerated their research activities in early 2026, with 141 institutions participating in A-share research, covering 111 stocks across 24 industries, totaling 673 research instances, significantly higher than the usual weekly level [1][3] - Chaojie Co., Ltd. received the highest attention with 48 research instances from 43 public fund institutions, and 5 institutions conducted follow-up research. The company focuses on precision fasteners for the automotive industry and is also involved in aerospace and electronics [1][2] - Aipeng Medical was the second most researched stock with 41 instances, focusing on pain management and innovative fields like brain-machine interfaces, providing smart medical devices and solutions [1][2] Group 2 - The computer industry had two companies in the top ten for research instances: Entropy Technology with 28 instances and Dineike with 17 instances. Entropy focuses on smart spaces and digital identity authentication, while Dineike specializes in smart community and hospital solutions [2][3] - The pharmaceutical and biological sector had the highest research instances at 89, covering 8 stocks, while the machinery and electronics sectors had 17 stocks each, with research instances of 85 and 62 respectively [3][4] - Other notable companies in the top ten for research instances included Guanglian Aviation (38), Zhejiang Mining (21), Hengyi Petrochemical (21), Shunhao Co., Ltd. (19), Caizhi Co., Ltd. (18), and Yiwang Yichuang (17) [3][4]

Core Insights - The Sci-Tech Innovation 50 (科创50) and Sci-Tech Innovation 200 (科创200) exhibit contrasting investment styles, offering investors different risk-return choices [1] - The Sci-Tech Innovation 50, as a leader in the Sci-Tech Innovation Board, has strong institutional attributes and consists mainly of benchmark enterprises heavily favored by institutions, particularly in the semiconductor sector [1] - In contrast, the Sci-Tech Innovation 200 showcases a significant small and micro-cap growth style, with constituent companies being national-level "specialized, refined, and innovative" enterprises that invest heavily in R&D [1] Investment Opportunities - The R&D expenditure as a percentage of revenue for the Sci-Tech Innovation 200 constituents is higher than that of the broader growth representative, the Sci-Tech Innovation 50 index, indicating a strong driver for future profit improvement and sustained high growth [1] - Small and medium-sized enterprises on the Sci-Tech Innovation Board are experiencing dual drivers of profit growth and valuation recovery [1] - The Sci-Tech Innovation 200 index focuses on hard technology sectors such as electronics, biomedicine, and machinery, covering emerging companies with a median market capitalization of approximately 7.8 billion [1] Product Offering - The newly launched Sci-Tech Innovation 200 ETF (国泰, 589223) provides investors with a convenient way to invest in small-cap hard technology companies on the Sci-Tech Innovation Board [1]

Core Viewpoint - The latest financing balance of the ChiNext stocks is 572.17 billion yuan, with a week-on-week increase of 2.21 billion yuan, indicating a positive trend in the market [1][7]. Financing Balance Overview - The total margin balance of ChiNext stocks reached 574.10 billion yuan, increasing by 2.24 billion yuan compared to the previous trading day, marking five consecutive days of growth [1][7]. - The financing balance specifically increased to 572.17 billion yuan, with a week-on-week rise of 2.21 billion yuan, also reflecting five consecutive days of increase [1][7]. - The margin trading balance for short selling reached 1.93 billion yuan, with a week-on-week increase of 37.89 million yuan [1][7]. Stocks with Increased Financing Balance - A total of 478 ChiNext stocks saw an increase in financing balance, with 39 stocks experiencing a growth rate exceeding 10% [1][7]. - The stock with the highest increase in financing balance is Porton Pharma, which saw a rise of 59.20%, despite a price drop of 6.40% on the same day [1][7]. - Other notable stocks with significant increases include Shaoyang Hydraulic and Ha Welding, with increases of 39.11% and 35.01% respectively [1][7]. Market Performance of Stocks with Increased Financing - Among the stocks with a financing balance increase of over 10%, the average price increase on the same day was 5.43%, with 31 stocks rising and two stocks hitting the daily limit [2][8]. - The top gainers included Rongxin Culture, Shaoyang Hydraulic, and Guoci Materials, with increases of 18.23%, 17.84%, and 14.93% respectively [2][8]. Capital Flow Analysis - On January 9, 25 stocks with increased financing balance saw net inflows of main funds, with Kunlun Wanwei, Guoci Materials, and Keta Power leading the inflows at 1.366 billion yuan, 236 million yuan, and 136 million yuan respectively [2][8]. - Conversely, 14 stocks experienced net outflows, with the largest outflows from Hailanxin, Sanbo Brain Science, and Chaojie Co., amounting to 701 million yuan, 406 million yuan, and 268 million yuan respectively [2][8]. Stocks with Decreased Financing Balance - A total of 471 stocks experienced a decrease in financing balance, with 15 stocks showing a decline of over 10% [4][11]. - The stock with the largest decrease is Zhishang Technology, which saw a drop of 23.09%, with a current financing balance of 365 million yuan [4][11]. - Other significant declines were noted in Deepwater Haina and Maipu Medical, with decreases of 18.15% and 17.08% respectively [4][11].

Company Performance - Hongbo Pharmaceutical's stock price reached a historical high, increasing by 9.48% to 45.15 yuan, with a trading volume of 11.64 million shares and a transaction value of 520 million yuan, resulting in a turnover rate of 9.27% [2] - The company's latest A-share total market capitalization is 6.302 billion yuan, and the A-share circulating market capitalization is 5.672 billion yuan [2] - For the first three quarters, the company achieved an operating income of 514 million yuan, representing a year-on-year growth of 31.43%, and a net profit of 34.7496 million yuan, with a year-on-year increase of 127.96% [2] Industry Overview - The pharmaceutical and biotechnology industry overall saw a slight increase of 0.12%, with 198 stocks rising and 3 stocks hitting the daily limit, including Di'an Diagnostics and Meian Health [2] - Conversely, 276 stocks experienced declines, with the largest drops recorded by Haishike, Sansheng Guojian, and Yinuosi, with declines of 6.41%, 4.22%, and 4.20% respectively [2] Financing Data - As of January 9, the latest margin trading balance for Hongbo Pharmaceutical was 232 million yuan, with a financing balance of 232 million yuan, reflecting an increase of 18.6192 million yuan over the past 10 days, which is a growth of 8.74% [2]

Core Viewpoint - 15 companies listed on the Sci-Tech Innovation Board have provided earnings forecasts for 2025, with 8 companies expecting profit increases, 3 companies expecting reduced losses, 2 companies expecting profit declines, and 2 companies expecting losses [1] Group 1: Earnings Forecast Overview - 53.33% of the companies forecast profit increases, with 8 out of 15 companies reporting positive earnings forecasts [1] - Among the companies expecting profit increases, 2 companies anticipate a net profit growth exceeding 100%, while 2 companies expect growth between 50% and 100% [1] Group 2: Individual Company Forecasts - Zhongke Lanyun (688332) expects the highest net profit growth of 371.51% [1] - Bai'ao Saituo (688796) and Qiangyi Co., Ltd. (688809) forecast net profit growth of 303.57% and 66.24%, ranking second and third respectively [1] - Other notable forecasts include: - Xinpeng Micro (688508) with a 66.00% increase - Muxi Co., Ltd. (688802) with a reduced loss of 54.22% [1] Group 3: Detailed Company Performance - Companies with profit increases: - Zhongke Lanyun: 371.51% [1] - Bai'ao Saituo: 303.57% [1] - Qiangyi Co., Ltd.: 66.24% [1] - Xinpeng Micro: 66.00% [1] - Daotong Technology (688208): 42.76% [1] - More Thread (688795): 41.36% [1] - Jianxin Superconductor (688805): 33.55% [1] - Yongxi Electronics (688362): 31.93% [1] - Youxun Co., Ltd. (688807): 22.01% [1] - Companies with reduced losses: - Muxi Co., Ltd.: 54.22% [1] - More Thread: 41.36% [1] - Zhenhua New Materials (688707): 14.73% [1] - Companies expecting losses: - Angrui Micro (688790): -19.44% [1] - Electric Wind Power (688660): -26.15% [1] - Companies expecting profit declines: - Zhongkong Technology (688777): -57.46% [1] - Aotewei (688516): -60.65% [1]

Market Overview - The market sentiment is significantly active, with the Wind All A Index rising by 5.11% in the first week of 2026, indicating a potential main upward wave of spring excitement[8] - The A-share market has surpassed the 30 trillion yuan mark in trading volume for the fifth time in history, after 73 trading days[8] Economic Indicators - In December, the Consumer Price Index (CPI) increased by 0.8% year-on-year, marking the highest level since March 2023, with a month-on-month increase of 0.1 percentage points[9] - The Producer Price Index (PPI) shows a significant upward trend since June 2025, indicating a recovery in the manufacturing sector[9] Sector Performance - Key sectors such as defense, electric power equipment, communication, and biomedicine have shown continuous improvement in revenue and net profit over the past two quarters, reflecting high-quality fundamental recovery[17] - The technology sector, particularly commercial aerospace, AI applications, and humanoid robotics, continues to lead market performance[8] Investment Strategy - The report suggests focusing on sectors with improving profitability, including beauty care, communication, basic chemicals, automotive, electric power equipment, biomedicine, electronics, and machinery[19] - The investment ratings for companies are categorized as "Buy" for expected growth of 5%-10%, "Hold" for -10% to +5%, and "Sell" for declines over 10%[25] Risk Factors - The report highlights potential risks associated with market volatility and regulatory changes impacting various sectors[24]

Market Overview - On January 9, the Shanghai Composite Index rose by 0.92%, with the total margin financing balance reaching 26,276.01 billion yuan, an increase of 69.91 billion yuan compared to the previous trading day [1] - The margin financing balance in the Shanghai market was 13,212.13 billion yuan, up by 34.55 billion yuan, while the Shenzhen market's balance was 12,979.40 billion yuan, increasing by 34.76 billion yuan [1] Industry Analysis - Among the industries tracked by Shenwan, 18 sectors saw an increase in financing balance, with the defense and military industry leading with an increase of 20.07 billion yuan [1] - The computer and electric equipment industries also showed significant increases in financing balance, with increases of 13.67 billion yuan and 13.64 billion yuan, respectively [1] Stock Performance - A total of 1,778 stocks experienced an increase in financing balance, accounting for 47.22% of the market, with 440 stocks seeing an increase of over 5% [1] - The stock with the highest increase in financing balance was Innovation Medical, which saw a balance of 612.87 million yuan, a 106.31% increase from the previous day, and its stock price rose by 10.00% [1] - Other notable stocks with significant increases in financing balance included Lifan Holdings and Portong Medical, with increases of 72.42% and 59.20%, respectively [1] Top Gainers and Losers - Among the top 20 stocks with the highest increase in financing balance, the average stock price rose by 5.21%, with the highest gainers being Shaoyang Hydraulic, Yuekang Pharmaceutical, and Guanshang Technology, with increases of 17.84%, 17.13%, and 13.04%, respectively [2] - Conversely, the stocks with the largest declines in financing balance included Tianrun Technology, which saw a decrease of 56.71%, and others like Geli'er and Changjiang Nengke, with declines of 34.23% and 31.56% [5]